Hanns-Ulrich Marschall
Hanns-Ulrich Marschall
Sahlgrenska Academy, Institute of Medicine, Department of Molecular and Clinical Medicine
Verified email at - Homepage
Cited by
Cited by
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist
SI Sayin, A Wahlström, J Felin, S Jäntti, HU Marschall, K Bamberg, ...
Cell metabolism 17 (2), 225-235, 2013
Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism
A Wahlström, SI Sayin, HU Marschall, F Bäckhed
Cell metabolism 24 (1), 41-50, 2016
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association For The Study Of The Liver
Journal of hepatology 51 (2), 237-267, 2009
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
O Ringdén, M Uzunel, I Rasmusson, M Remberger, B Sundberg, ...
Transplantation 81 (10), 1390-1397, 2006
Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates
A Glantz, HU Marschall, LÅ Mattsson
Hepatology 40 (2), 467-474, 2004
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis
F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ...
New England Journal of Medicine 375 (7), 631-643, 2016
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ...
Gastroenterology 145 (3), 574-582. e1, 2013
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
D Ellinghaus, L Jostins, SL Spain, A Cortes, J Bethune, B Han, YR Park, ...
Nature genetics 48 (5), 510-518, 2016
Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management
F Lammert, HU Marschall, A Glantz, S Matern
Journal of hepatology 33 (6), 1012-1021, 2000
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ...
Gastroenterology 148 (4), 751-761. e8, 2015
Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota
J Wang, LB Thingholm, J Skiecevičienė, P Rausch, M Kummen, JR Hov, ...
Nature genetics 48 (11), 1396-1406, 2016
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice
P Fickert, A Fuchsbichler, M Wagner, G Zollner, A Kaser, H Tilg, R Krause, ...
Gastroenterology 127 (1), 261-274, 2004
Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis
TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ...
Gastroenterology 152 (8), 1975-1984. e8, 2017
Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses
C Ovadia, PT Seed, A Sklavounos, V Geenes, C Di Ilio, J Chambers, ...
The Lancet 393 (10174), 899-909, 2019
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study
R Olsson, KM Boberg, OS de Muckadell, S Lindgren, R Hultcrantz, ...
Gastroenterology 129 (5), 1464-1472, 2005
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ...
Nature genetics 45 (6), 670-675, 2013
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations
G Zollner, HU Marschall, M Wagner, M Trauner
Molecular pharmaceutics 3 (3), 231-251, 2006
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice
M Wagner, E Halilbasic, HU Marschall, G Zollner, P Fickert, C Langner, ...
Hepatology 42 (2), 420-430, 2005
Whole-genome Sequencing of Patients With Rare Diseases in a National Health System
OWH NIHR BioResource for the 100,000 Genomes Project, Kingston N, Walker N ...
Nature 583, 96-102, 2020
The system can't perform the operation now. Try again later.
Articles 1–20